Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 300 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Isotonic Solution, Intravenous Clear all
Recruiting Phase 2 Interventional

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459
View directory record Official record
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions
Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion
Biological · Drug · Other
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

NCT03837470
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Hypertonic Saline as Therapy for Pediatric Concussion

NCT01612494
View directory record Official record
Conditions
Pain
Interventions
Hypertonic Saline, Normal Saline
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
4 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

NCT01332253
View directory record Official record
Conditions
Tonsillectomy
Interventions
Intravenous ibuprofen, Normal Saline
Drug · Other
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Louisville, Kentucky • Newark, New Jersey • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 4, 2026, 3:43 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

NCT03514537
View directory record Official record
Conditions
Frail Elderly Syndrome, Aging, Degenerative Disease
Interventions
Microcannula harvest adipose stromal tissues, Centricyte 1000, Sterile Normal Saline IV Deployment of cSVF, Liberase, Saline Solution
Procedure · Device · Drug
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 4, 2026, 3:43 AM EDT
Withdrawn Not applicable Interventional

Reexamining Hypotonic Intravenous Fluid Use

NCT02667977
View directory record Official record
Conditions
Hyponatremia
Interventions
0.9 Normal Saline, 0.45 Normal Saline
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

NCT01732211
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
PD 0360324, Normal Saline for injection
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

NCT01518881
View directory record Official record
Conditions
Ebola Virus Infection
Interventions
TKM-100201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

NCT01539590
View directory record Official record
Conditions
Myocardial Infarction
Interventions
BB3, Normal saline
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
21 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New Haven, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Not applicable Interventional Results available

Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)

NCT02547779
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
10,421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

NCT02041715
View directory record Official record
Conditions
Ebola Virus Infection
Interventions
TKM-100802 for Injection, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Oct 4, 2026, 3:43 AM EDT
Recruiting Phase 2Phase 3 Interventional

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

NCT07217873
View directory record Official record
Conditions
Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
Interventions
Ferric carboxymaltose IV, Normal Saline (Placebo)
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 19 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT03752905
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01, Normal saline
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Redwood City, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

NCT01978535
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
Iron infusion, Normal saline infusion
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Early Phase 1 Interventional

Combined IV and Topical TXA in Major Spine Surgery

NCT04797156
View directory record Official record
Conditions
Spine Surgery, Back Pain
Interventions
High Dose Tranexamic acid, Low Dose Tranexamic acid, Tranexamic acid Topical, Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 4 Interventional Results available

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

NCT00808665
View directory record Official record
Conditions
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions
Dexmedetomidine, 0.9% Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 2Phase 3 Interventional

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

NCT04428372
View directory record Official record
Conditions
Hemodialysis Complication, Hemodynamic Instability
Interventions
Mannitol, 0.9% saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 1 Interventional Results available

High Dose Vitamin C in Cardiac Surgery Patients

NCT02762331
View directory record Official record
Conditions
Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
Interventions
Ascorbic Acid, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 4, 2026, 3:43 AM EDT
Withdrawn Not applicable Interventional

Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients

NCT00709293
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Heart Transplantation
Interventions
Anti-Thymocyte Globulin, Normal Saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 4, 2026, 3:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 4, 2026, 3:43 AM EDT
Not yet recruiting Phase 4 Interventional

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

NCT07686692
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions
Ferric derisomaltose, Placebo (normal saline)
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 3:43 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

NCT00738699
View directory record Official record
Conditions
Ovarian Cancer
Interventions
MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 4, 2026, 3:43 AM EDT